GleamWall
中文EN

JAZZ Jazz Pharmaceuticals plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1232524 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.5%
TTM net income YoY155.9%
TTM EPS YoY154.9%
Revenue 3-yr CAGR7.5%
Net income 3-yr CAGR37.1%

Margins

Gross margin—
Operating margin9.0%
Net margin4.4%
FCF margin34.4%
EBITDA margin9.8%

Returns

ROE5.1%
ROA1.8%
ROIC (approx.)4.3%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets65.1%
Debt / equity1.33x
Current ratio1.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income8.22x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.24B$1.21B$1.07B$1.20B$1.13B$1.05B$897.80M$1.09B
R&D expense$211.90M$207.50M$196.00M$213.91M$198.20M$189.90M$180.70M$240.50M
SG&A expense$407.90M$389.20M$352.70M$406.21M$530.60M$358.40M$514.00M$369.29M
Operating income-$413.40M$248.20M$336.60M$254.53M$57.50M-$686.40M-$55.90M$190.77M
Pretax income-$458.90M$211.00M$299.20M$208.54M$9.00M-$735.60M-$109.80M$133.22M
Income tax$24.50M$18.10M$6.10M$4.96M-$242.40M-$17.20M-$17.80M-$57.91M
Net income-$483.40M$192.80M$293.10M$203.45M$251.40M-$718.50M-$92.50M$191.12M
EBITDA-$406.30M$257.30M$345.70M$263.94M$67.40M-$674.50M-$45.50M$200.33M
EPS (basic)-7.483.054.73—4.14-11.74-1.52—
EPS (diluted)-7.482.784.43—4.08-11.74-1.52—
Weighted avg. shares (diluted)64.70M69.40M66.10M—61.60M61.20M61.00M—
Balance sheet
Cash & equivalents$2.04B$1.62B$1.84B$1.39B$1.33B$1.19B$1.86B$2.41B
Receivables$873.70M$880.90M$836.30M$830.70M$764.36M$714.00M$652.99M$716.76M
Inventory$454.00M$443.00M$437.50M$417.00M$483.11M$504.99M$492.78M$480.44M
Current assets$4.61B$3.97B$4.58B$4.17B$3.76B$3.35B$4.13B$4.63B
PP&E, net$224.80M$212.00M$203.10M$199.90M$188.91M$184.97M$178.87M$173.41M
Goodwill$1.80B$1.80B$1.80B$1.83B$1.83B$1.84B$1.76B$1.72B
Intangibles$4.17B$4.03B$4.20B$4.43B$4.57B$4.77B$4.72B$4.76B
Total assets$12.00B$11.08B$11.86B$11.66B$11.36B$10.94B$11.53B$12.01B
Current liabilities$2.53B$2.23B$2.25B$2.24B$2.27B$2.07B$1.22B$1.04B
Short-term debt$1.02B$1.02B$1.03B$1.03B$1.03B$1.03B$31.00M$31.00M
Long-term debt$4.55B$3.33B$4.32B$4.33B$4.33B$4.34B$5.34B$6.08B
Total debt$5.57B$4.35B$5.35B$5.36B$5.36B$5.36B$5.37B$6.11B
Total liabilities$7.81B$6.28B$7.33B$7.34B$7.40B$7.24B$7.36B$7.92B
Shareholders' equity$4.19B$4.80B$4.53B$4.32B$3.96B$3.71B$4.17B$4.09B
Net debt$3.53B$2.73B$3.51B$3.97B$4.04B$4.17B$3.51B$3.70B
Shares outstanding———61.44M———60.63M
Cash flow statement
Operating cash flow$506.10M$415.70M$408.20M$362.52M$474.70M$88.80M$429.80M$398.58M
Capital expenditure$16.20M$18.10M$19.70M$16.73M$15.20M$12.90M$13.90M$13.29M
Free cash flow$489.90M$397.60M$388.50M$345.79M$459.50M$75.90M$415.90M$385.29M
Investing cash flow-$1.08B$354.90M$123.10M-$372.16M-$327.80M-$641.00M-$169.00M-$193.29M
Financing cash flow$993.70M-$994.50M-$78.50M$75.44M-$10.90M-$124.40M-$813.50M-$8.28M
Depreciation & amortization$7.10M$9.10M$9.10M$9.40M$9.90M$11.90M$10.40M$9.56M
Stock-based compensation$77.20M$73.30M$74.50M$70.85M$88.10M$64.50M$67.70M$70.19M
Share buybacks$225.00M——$0$0——$0

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.